Clinical trial
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
NCT01784861 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- May 3, 2013
- Completion date
- August 19, 2020
- Enrollment
- 23 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.